A Novel Angiotensin Type I Receptor Antagonist, XXXX , Prevents @entity632 -induced Cardiotoxicity in @entity35 .

@entity632 @entity296 @entity712 @entity3105 @entity35 @entity48152
Angiotensin receptor blockers (ARBs) have organ-protective effects in @entity712 and may be also effective in @entity632 -induced @entity296 (DOX-CMP); however, the efficacy of ARBs on the prevention of DOX-CMP have not been investigated. We performed a preclinical experiment to evaluate the preventive effect of a novel ARB, @entity48152 , in DOX-CMP. All animals underwent echocardiography and were randomly assigned into three groups: treated daily with vehicle ( @entity3105 -only group, n=22), 5 mg/kg of @entity48152 (Low-fima group, n=22), and 10 mg/kg of @entity48152 (High-fima group, n=19). @entity3105 was injected once a week for six weeks. Echocardiography and hemodynamic assessment was performed at the 8th week using a miniaturized conductance catheter. Survival rate of the High-fima group was greater (100%) than that of the Low-fima (75%) and @entity3105 -only groups (50%). Echocardiography showed preserved left ventricular (LV) ejection fraction in the High-fima group, but not in the @entity3105 -only group (P=0.002). LV dimensions increased in the @entity3105 -only group; however, remodeling was attenuated in the Low-fima and High-fima groups. Hemodynamic assessment showed higher dP/dt in the High-fima group compared with the @entity3105 -only group. A novel ARB, @entity48152 , may prevent @entity3105 -CMP and improve survival rate in a dose-dependent manner in a @entity35 model of DOX-CMP and could be a treatment option for the prevention of DOX-CMP.
